Back to Cell Types

NCI-H1355Homo sapiens (Human)Cancer cell line

Also known as: NCIH1355, H-1355, H1355

🤖 AI SummaryBased on 13 publications

Quick Overview

Human small cell lung cancer cell line with known RB1 mutations and potential for drug sensitivity studies.

Detailed Summary

The NCI-H1355 cell line is a human small cell lung cancer (SCLC) cell line derived from a patient with metastatic disease. It is characterized by the presence of RB1 mutations, which are common in SCLC and play a critical role in cell cycle regulation. This cell line has been used in studies investigating the molecular mechanisms of SCLC, including the role of RB1 in tumor suppression and the identification of potential therapeutic targets. The cell line exhibits specific protein expression profiles and has been utilized in drug sensitivity assays to evaluate the efficacy of various anticancer agents. Its genetic background makes it a valuable model for studying SCLC biology and developing targeted therapies.

Research Applications

Molecular mechanisms of SCLCRB1 mutation analysisDrug sensitivity studiesTherapeutic target identification

Key Characteristics

RB1 mutationsSmall cell lung cancer originMetastatic disease backgroundProtein expression profiling

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1464
Species	Homo sapiens (Human)
Tissue Source	Pleural effusion[UBERON:UBERON_0000175]

Donor Information

Age	53
Age Category	Adult
Sex	Male
Race	caucasian

Disease Information

Disease	Lung adenocarcinoma
Lineage	Lung
Subtype	Lung Adenocarcinoma
OncoTree Code	LUAD

DepMap Information

Source Type	ATCC
Source ID	ACH-000666_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Glu285Lys (c.853G>A)	Unspecified	Temperature-sensitive	PubMed=23851445, PubMed=17260012
MutationSimple	KRAS	p.Gly13Cys (c.37G>T)	Heterozygous	-	Unknown, Unknown, PubMed=28273451, PubMed=25230021, PubMed=24224046, PubMed=22705003
MutationSimple	BRCA2	p.Gly2044Asp (c.6131G>A)	Homozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

12,13

D13S317

12

D16S539

8,13

D18S51

11,17

D19S433

14

D21S11

31,32.2

D2S1338

21,23

D3S1358

18

D5S818

11,13

D7S820

12

D8S1179

14,16

FGA

22,23

Penta D

13,15

Penta E

14

TH01

9

TPOX

9,12

vWA

14,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Linnoila R.I.

Oncogene 7:743-749(1992).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources